Key result
Specific HLA-DR antigens are linked to in vitro immune reactivity against therapeutic insulin components.
Observational
Answers are grounded in this paper and cite their sources.
Reveals HLA antigen associations with immune responses to animal insulins in diabetic patients, indicating major histocompatibility complex control.
Genes in the major histocompatibility complex of mice and guinea pigs control immunologic responsiveness to insulins from other animal species. In order to determine if similar genetic control exists in man, we have examined lymphocyte proliferation responses to components of therapeutic insulins by employing lymphocytes from diabetic patients that receive insulin. Distinct groups of individuals demonstrated positive lymphocyte proliferative responses to beef insulin, beef and pork insulin, beef proinsulin, pork proinsulin, and protamine. Lymphocytes from the patient population were typed for the HLA-A, B, C, and DR antigens. An increased frequency of certain HLA antigens was found in those individuals that responded to the following therapeutic insulin components: beef, HLA-DR4; beef and pork, HLA-DR3; beef proinsulin, HLA-BW4, CW2, CW5, DR2, and DR5; protamine, HLA-CW3, CW5, and DR7. The results demonstrate that the human immune system recognized the structural differences between human and beef and/or pork insulin. These differences are two amino acids in the A chain, alpha loop, of beef insulin and the single terminal amino acid, alanine, which is common to pork and beef insulins. Positive responses to both beef proinsulin and pork proinsulin demonstrated the capability of restricted recognition of more complex proteins represented by the C-peptide in these insulin preparations. Lymphocyte proliferative responses to protamine were also restricted, which suggests a genetic control to this antigen. The association of these responses with HLA alloantigens strongly suggests that genes within the human major histocompatibility complex control recognition and lymphocyte response to therapeutic insulin components.
No takes yet. Share an insight, caveat, or question.
Mann et al. (1983) conducted an observational in Diabetes mellitus. Therapeutic insulin components (beef insulin, pork insulin, beef proinsulin, pork proinsulin, and protamine) and HLA alloantigens was evaluated on In vitro lymphocyte proliferative response to therapeutic insulin components and association with HLA antigens. Specific HLA antigens were associated with in vitro lymphocyte proliferative responses to therapeutic insulin components, including HLA-DR4 for beef insulin and HLA-DR3 for beef and pork insulin.
Synapse has enriched 10 related papers. Consider them for comparative context: